Mundelein, Illinois, April 19, 2011 - Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, announced today an amended distributorship agreement with Laboratory Supply Company (LABSCO). This agreement, which automatically renews for up to four successive one-year periods, is for Sysmex reagents, controls and instruments including the Sysmex pocH-100i™, Sysmex KX-21N™, the Sysmex XS-1000i™, XT-Series and XE-Series Automated Hematology Analyzers. The agreement is effective immediately and continues until March 31, 2015. This agreement represents Sysmex America’s second amended distributorship agreement with LABSCO.
"Sysmex America has enjoyed a successful partnership with LABSCO for several years built on trust, confidence and collaboration. LABSCO’s clinical lab and instrumentation expertise/representation and focus on <150 bed hospitals, POL/alternate site, and reference lab markets will serve Sysmex America well as we better meet the needs of our customers," said Michael Messner, Director, Distributor-Primary Care, Sysmex America, Inc.
Sysmex America offers a variety of products to a wide range of segments within the healthcare industry. In order to reach all customers in the United States, Latin America and Canada, the company partners with a network of distributors who are experts in their respective areas.
About LABSCO
Laboratory Supply Company was founded by Charles (Charlie) Davis in Louisville, Kentucky in 1972. LABSCO has nine distribution centers and has grown to be the largest privately held distributor of clinical laboratory products in the United States. LABSCO is known for its expertise in the clinical laboratory, but is also a full line distributor of laboratory supplies and instrumentation and medical/surgical products to the physician office laboratory (POL) and other alternate care settings. LABSCO was recently acquired by Frazier Healthcare.
About Frazier Healthcare
Founded in 1991, Frazier Healthcare is a leading provider of growth equity and venture capital to high growth and emerging healthcare service, biopharma and medical device companies. With over $1.8 billion under management across seven funds, Frazier Healthcare has invested in over 100 companies across the entire developmental spectrum. From seed stage venture investments to leveraged recapitalizations of cash generating companies, Frazier Healthcare has established itself among entrepreneurs and seasoned executives as a preferred partner to help create and grow successful healthcare companies.